CLSDQ (Clearside Biomedical) Tariff Resilience Score: 8/10 (As of Jul. 06, 2026)


CLSDQ Clearside Biomedical Inc CLSDQ
49 GF Score
Price $0.13
GF Value $6.34
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical Tariff Resilience Score?

Clearside Biomedical CLSDQ 49 Tariff Resilience Score is 8 as of Jul. 06, 2026. GuruFocus rates CLSDQ with a GF Score™ of 49/100 and a GF Value™ of $6.34 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,369 Biotechnology companies, Clearside Biomedical ranks better than 98.69% on this metric.

Clearside Biomedical has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Clearside Biomedical has Clearside Biomedical Inc is highly resilient due to its focus on the domestic market and industry-specific exemptions. Its supply chain is less exposed to international tariffs, and it has strong pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Clearside Biomedical might have Highly Resilient.

Clearside Biomedical  (OTCPK:CLSDQ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Clearside Biomedical Tariff Resilience Score Related Terms

CLSDQ vs LYRA, EVFM, ATXI: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Clearside Biomedical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearside Biomedical Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Tariff Resilience Score falls into.


CLSDQ
49GF Score
Clearside Biomedical Inc CLSDQ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Clearside Biomedical (CLSDQ) has a Tariff Resilience Score of 8 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Clearside Biomedical ranks #18 out of 1369 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Clearside Biomedical's Tariff Resilience Score too high?
Clearside Biomedical's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Clearside Biomedical's value of 8 is 100% above this industry median. Based on the distribution chart, Clearside Biomedical ranks #18 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Tariff Resilience Score compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #18 out of 1369 companies for Tariff Resilience Score. This places Clearside Biomedical in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Clearside Biomedical's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clearside Biomedical's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearside Biomedical's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current Tariff Resilience Score is 8 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clearside Biomedical (CLSDQ) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34. GuruFocus considers Clearside Biomedical to be Possible Value Trap.

Key valuation signals for CLSDQ:

  • Tariff Resilience Score: 8
  • GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
  • GF Score™: 49/100 with 7 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1369)

No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clearside Biomedical Business Description

Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for CLSDQ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$6.34
GF Value